Excellos Ensures Reliability and Patient Safety with XiltriX
This case study is available as a downloadable PDF for offline reading.
Choosing the right PBMCs for your research and product development needs
What you need to know about choosing peripheral blood mononuclear cells for your research and development projects What are PBMCs? Human peripheral blood mononuclear cells (PBMCs) are key components of the body’s immune system. PBMCs are typically isolated from whole blood by apheresis and used for a variety of downstream applications, such as feeder […]
Allogeneic Cell Therapy Advances at AACR 2024
American Association for Cancer Research (AACR) held their 2024 annual meeting in San Diego CA. This conference served as a platform for groundbreaking advancements in allogeneic cell therapy highlighted across a range of diseases. Safeguarding allogeneic cell therapy products Among the noteworthy developments were discoveries from Century Therapeutics whose presentation of preclinical data revealed […]
3 Key Bottlenecks in Cell Therapy Supply Chains
Cell Therapy Supply Chain With 1920 ongoing clinical trials as of Q4 2023, the pipeline for new therapies is rich in diversity of diseases under investigation and is continuing to grow. A major follow-on question is whether the gene and cell therapy supply chain is ready to handle what may be a tidal wave of […]
Autoimmune Therapy Excitement Builds at Advanced Therapies Week 2024
Robust pipeline demonstrated at Advanced Therapies Week 2024 As we reflect on the monumental strides made in 2023 within the field of cell and gene therapy, Advanced Therapies Week 2024 served as an inspiring launchpad for the year ahead. Groundbreaking approvals like gene therapies for sickle cell disease brought hope for rare illnesses, while advances […]
Excellos is excited to partner with TC BioPharm to enable novel cell therapies
TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements EDINBURGH, Scotland, Oct. 25, 2023 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced it has selected Excellos, a San Diego based […]
Single-Cell Analysis of T Cells – Improved Prediction of Disease Risk
The La Jolla researchers are studying how small changes in gene expression can influence the function of immune cells during infection. Single-cell analysis was performed on activated CD4+ T cells from 89 healthy donors. It turns out that the old adage of “one gene, one protein” is not precisely true. In reality, as research on […]
Stem Cell Transduction Efficiency – Managing Donor Variance
Gene therapy, and in particular, therapy involving genetically modified stem cells, is one of the most promising methods for treating genetic disease and defects, and has therefore become a popular focus of research and development. In recent years, using adenoviral vectors to deliver modified genes has become standard practice. Adeno-associated viruses (AVVs) are easy to […]
Single-Cell Immune Profiling Reveals Remarkable Changes Associated with COVID-19
Researchers at the La Jolla Institute for Immunology cite using Excellos sourced healthy donor starting material to carry out single-cell immune profiling for their research on severe COVID-19. [1] Great strides have been made in fighting the SARS-CoV-2 virus, the most noteworthy being the development and distribution of the COVID-19 vaccine. However, we must keep […]
Trogocytosis – A Case of T cell Identity Theft Offers Essential Clue to Solving MS
A case of immune T cell identity theft (trogocytosis) gave German scientists the vital clue they needed to understand a key mechanism behind the development of multiple sclerosis (MS). In a recently published paper, scientists at the Institute of Neuropathology in Gottingen, Germany, describe new research that could help doctors treat MS. [1] The key […]